The biotechnology sector is in focus following reports that AbbVie (ABBV) is nearing an acquisition of Apogee Therapeutics ...
Biotech stocks are outperforming the broader market as growth investors return and M&A activity supports valuations across ...
Investor's Business Daily on MSN
This biotech's LSD-based drug just treated depression. Now the stock is sky-high.
Definium Therapeutics skyrocketed Monday after its psychedelics-based depression treatment scored a "best-case" win in ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...
In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...
Vir Biotechnology develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV. It generates revenue primarily through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results